PARP1 and myeloproliferative neoplasm: Accordingly, there has been substantial interest in exploring the therapeutic potential of PARP inhibition in various myeloid neoplasms, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and others.